<DOC>
	<DOCNO>NCT00336843</DOCNO>
	<brief_summary>In order improve clinical result high-dose chemotherapy autologous stem cell transplantation B-cell non-Hodgkin 's lymphoma , Zevalin add condition regimen . Investigators expect radioimmunotherapy Zevalin plus busulfan , cyclophosphamide etoposide regimen improve survival relapse poor-risk B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Zevalin Plus BuCyE High-dose Therapy B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Title : Combining 90Y-Ibritumomab tiuxetan ( Zevalin ) high-dose chemotherapy BuCyE autologous stem cell transplantation patient relapse , refractory , high-risk B-cell non-Hodgkin 's lymphoma - open-labeled phase II study . Study design : Prospective , multicenter , open-labeled , phase II trial . Study objective : - Primary : event-free survival time follow autologous stem cell transplantation 90Y-Ibritumomab tiuxetan BuCyE high-dose chemotherapy patient relapse , refractory , high-risk B-cell non-Hodgkin 's lymphoma - Secondary : overall survival response rate toxicity treatment combination Treatment : Z-BuCyE Regimen - Day 21 : rituximab , 250 mg/m2 , I.V . - Day 14 : rituximab , 250 mg/m2 , I.V . 90Y-Ibritumomab tiuxetan , 0.4 mCi/kg , I.V . - Day 7 , 6 , 5 : busulfan 3.2 mg/kg I.V . - Day 5 , 4 : etoposide 200 mg/m2 I.V . every 12 hour - Day 3 , 2 : Cytoxan 50 mg/kg I.V . - Day 0 : autologous stem cell infusion</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm Bcell NHL chemotherapysensitive relapse , partial response 1st line chemotherapy , complete response 1st line chemotherapy high IPI score diagnosis Age &lt; 65 year old WHO performance status ( PS ) 02 ANC &gt; 1,500/mm3 , platelet &gt; 100,000/mm3 Cr &lt; 2.0 mg % Ccr &gt; 50 mL/min Transaminase &lt; 3X upper normal value Bilirubin &lt; 2 mg/dL Life expectancy least 3 month Written inform consent Optimal harvest autologous stem cell ( CD34+ cell &gt; 5 million/kg plus 2 million/kg backup ) Prior hematopoietic stem cell transplantation Prior RIT Prior external radiation &gt; 25 % active bone marrow CNS involvement nonHodgkin 's lymphoma Serious comorbid diseases HIV HTLV1 associate malignancy History malignant disease previous 5 year , except squamous cell basal cell carcinoma skin stage I uterine cervical carcinoma cervical carcinoma situ Known hypersensitivity murine antibodies/proteins Pregnant breast feed female patient , adult without effective contraception 12 month RIT Persistent toxic side effect prior therapy Prior biologic immunotherapy le 4 week prior entry study Investigational drug less 4 week prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Zevalin</keyword>
	<keyword>B-cell non-Hodgkin 's lymphoma</keyword>
	<keyword>autologous stem cell transplantation</keyword>
	<keyword>BuCyE regimen</keyword>
</DOC>